ACI: Drug Safety, Pharmacovigilance & Risk Management Forum – Agenda Highlights Announced

July 5, 2012 - PRLog -- The American Conference Institute, organizers of the Drug Safety, Pharmacovigilance and Risk Management Forum, taking place October 22 - 24, 2012 at the Union League in Philadelphia, today announced key highlights from this year’s program agenda.

Participation by Industry Risk Management Experts

Attendees at this year’s conference will hear directly from an unprecedented group of industry executives directly responsible for implementing company risk plans.  Companies at this year’s program include:  Amag Pharmaceuticals, Baxter Healthcare, BioMarin Pharmaceuticals, Ely Lilly & Co., Genzyme Corporation, Johnson & Johnson, and Purdue Pharma.  .

Hear Directly from the FDA

As scrutiny on the pharmaceutical industry continues to intensify, hear directly from Carla Cartwright, Associate Chief Counsel for the FDA.  She will offer insights on Effectively Negotiating a REMS Strategy with the FDA.  

Drug Production is Going Global – Negotiate Deals in Foreign Countries

As manufacturing outsourcing becomes more of the norm for pharmaceutical companies, it is increasingly necessary to develop the skills to negotiate deals in foreign countries.  The European Medicines Agency recently announced that it would be investigating the safety of a manufacturer’s drugs, after reporting deficiencies were discovered.  Learn how to minimize risk when conducting all or part of your manufacturing abroad.    

Program Director Stacey Evans remarked, “This conference is the culmination of many weeks of detailed research with industry leaders at more than 30 pharmaceutical manufacturers.”

Full information on the forum can be found at www.americanconference.com/drugsafety